Literature DB >> 12788039

Profound skeletal muscle depletion of alpha-dystroglycan in Walker-Warburg syndrome.

Cecilia Jiménez-Mallebrera1, Silvia Torelli, Susan C Brown, Lucy Feng, Martin Brockington, Caroline A Sewry, Daniel Beltrán-Valero De Bernabé, Francesco Muntoni.   

Abstract

Walker-Warburg syndrome (WWS) is an autosomal recessive disorder characterized by the combined involvement of the central nervous and skeletal muscle systems. Although the molecular basis of WWS remains unknown, defects in the muscle fibre basal lamina are characteristic of other forms of congenital muscular dystrophy (CMD). In agreement with this, some forms of CMD, due to glycosyltransferase defects, display a reduction in the immunolabelling of alpha-dystroglycan, whilst beta-dystroglycan labelling appears normal. Here we describe an almost complete absence of alpha-dystroglycan using both immunohistochemistry and immunoblotting in two patients with WWS. In addition, there was a mild reduction of laminin-alpha 2. In contrast, immunohistochemical labelling of perlecan and collagen VI was normal. Linkage analysis excluded the recently identified POMT1 locus, responsible for a proportion of WWS cases. These results confirm that WWS is a genetically heterogeneous condition and suggest that disruption of the alpha-dystroglycan/laminin-alpha 2 axis in the basal lamina may play a role in the degeneration of muscle fibres in WWS-also in cases not due to POMT1 defects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788039     DOI: 10.1016/s1090-3798(03)00042-4

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  5 in total

1.  POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome.

Authors:  J van Reeuwijk; M Janssen; C van den Elzen; D Beltran-Valero de Bernabé; P Sabatelli; L Merlini; M Boon; H Scheffer; M Brockington; F Muntoni; M A Huynen; A Verrips; C A Walsh; P G Barth; H G Brunner; H van Bokhoven
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

2.  Mutational and functional analysis of Large in a novel CHO glycosylation mutant.

Authors:  Jennifer T Aguilan; Subha Sundaram; Edward Nieves; Pamela Stanley
Journal:  Glycobiology       Date:  2009-05-21       Impact factor: 4.313

3.  A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity.

Authors:  Cecilia Jimenez-Mallebrera; Silvia Torelli; Lucy Feng; Jihee Kim; Caroline Godfrey; Emma Clement; Rachael Mein; Stephen Abbs; Susan C Brown; Kevin P Campbell; Stephan Kröger; Beril Talim; Haluk Topaloglu; Ros Quinlivan; Helen Roper; Anne M Childs; Maria Kinali; Caroline A Sewry; Francesco Muntoni
Journal:  Brain Pathol       Date:  2008-08-07       Impact factor: 6.508

Review 4.  Walker-Warburg syndrome.

Authors:  Jiri Vajsar; Harry Schachter
Journal:  Orphanet J Rare Dis       Date:  2006-08-03       Impact factor: 4.123

5.  Development of rabbit monoclonal antibodies for detection of alpha-dystroglycan in normal and dystrophic tissue.

Authors:  Marisa J Fortunato; Charlotte E Ball; Katrin Hollinger; Niraj B Patel; Jill N Modi; Vedika Rajasekaran; Dan J Nonneman; Jason W Ross; Eileen J Kennedy; Joshua T Selsby; Aaron M Beedle
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.